echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Treat chronic hepatitis B! Zhengda Tianqing TQA3605 tablets were first approved for clinical use

    Treat chronic hepatitis B! Zhengda Tianqing TQA3605 tablets were first approved for clinical use

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    Author: Sunshine

    August 26, clinical trials show default permission CDE official website, CTTQ clinical trial application TQA3605 piece obtained SFDA, alone or in combination with nucleoside (acid) treatment of chronic hepatitis


    Chronic hepatitis B is a chronic disease in which hepatitis B virus (HBV) is continuously infected for more than 6 months, and the liver undergoes varying degrees of inflammatory necrosis (or) fibrosis


    China is a big country for hepatitis B.


    After the hepatitis B virus enters the host, it will integrate its genome into the NDA in the nucleus of the host's liver cells to form a covalently closed circular DNA (cccDNA), and then use the host to synthesize mRNA and the protein required for viral particle assembly


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.